Seattle Genetics came into being in 1998 with Dr Clay Siegall being a co-founder. He is the president, chairman of the board and CEO of the company. Through his leadership, the company has attained over six hundred and seventy-five dollars through capital- raising activities from both private and public financing inclusive of the 2001 initial offering to the public. He has also led the company into building an improved pipeline of cancer therapies which are antibody-based that was approved in 2011 by the United States Food and Drug Administration. Dr Clay worked with Bristol-Myers Squibb research pharmaceutical institute before co-founding Seattle genetics since 1988 and left in 1991. He currently has fifteen patents and is an author of over seventy publications and also serves at Alder Biopharmaceuticals as a member of the board. Dr Clay Siegall attained his PhD at the University of Washington in Genetics and his B.S. at Maryland University in Zoology.
Seattle Genetics is a company that is passionate about the human antibodies, and this has seen the company manipulating, studying and packaging drugs using these antibodies since the company was founded. They make these antibodies in such a way that they can deliver a lethal payload to a cancer cell that destroys it from the inside. Seattle Genetics is the most prominent biotech company in Washington and has over nine hundred employees and has a market value of over ten billion US dollars. It has an intention of adding over two hundred more employees who will enable it to develop more. The company made a sale of about four hundred and eighteen US dollars in 20016 which was an up by forty-six percent from the 20014 sales. The price of shares of the company has tripled in the previous five years with share prices moving from twenty US dollars per share to sixty-six US dollars in mid-May. The company, according to researchers, has developed due to more investment in research on some promising drugs. Siegall is confident that the company will grow more in the future through progressive research on cancer suppression and cure. According to him, the road is not easy and will never be easy, but he tries very toughly not to be caught up in its ups and downs. His advice to the upcoming entrepreneurs is never to take ‘no’ for an answer and to take all shots since they miss out a hundred percent on shots they fear to take.